Imugene (ASX; IMU) is an immuno-oncology focused biopharmaceutical company developing HER2 +ve gastric and breast cancer vaccines.
Our lead product is HER-Vaxx, a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER-2. HER-2 is a known and validated receptor over-expressed on various tumours including gastric, breast, ovarian and pancreatic cancers.
HER-Vaxx has successfully completed a Phase I study in breast cancer and the next stage of development will be a Phase II study in gastric cancer.
Imugene’s corporate headquarters are located in Melbourne, Australia with the scientific team in Vienna, Austria.